|
Galapagos is a mid-size biotechnology company specialized in the discovery and early development of small molecule and antibody therapies with novel modes-of-action. With a strong team of first-class researchers, Galapagos is progressing one of the largest pipelines in biotech: six clinical and over 50 discovery/pre-clinical programs. Galapagos has a strong investor base, with a long term commitment to the biotech industry. Whether you are a current investor in Galapagos or are evaluating Galapagos as a potential investment opportunity, we hope you find this section of the website informative. The documents below provide a brief introduction to Galapagos. To receive an investor pack (available in English or Dutch), please contact the Investor Relations team.
|
|
Disclaimer |
